Norton David Y's Form 4 filing
Keenova Therapeutics plc (MNKTQ) · filed Aug 9, 2021
- Accession no.
- 0001235110-21-000021
- Filed
- Aug 9, 2021, 9:09 AM ET
- Trade date
- Aug 5, 2021
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market sales total $1.33K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Norton David YCIK 0001529193 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 5, 2021 | Ordinary Shares | SSaleDisposed | −5,080 | $0.2626F1 | −$1,334.01 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price represents a weighted average. The shares were sold in multiple transactions at prices ranging from $0.2506 to $0.2628, inclusive. Mr. Norton will provide, upon request of the SEC staff, Mallinckrodt plc or a shareholder of Mallinckrodt plc complete information regarding the number of shares purchased at each price within the range.
Referenced by the price of 1 transaction in Table I.
Remarks
This Form 4 constitutes a notice to the Issuer for purposes of Part V of the Companies Act 2014.